The revenue and EPS miss is significant, but the stock's reaction will likely be dominated by the binary catalysts ahead: the Quimilza PDUFA on Dec 12, 2026, and the GSK litigation judgment in Q4 2026/Q1 2027. A favorable litigation outcome (reversion of Jemperli rights) would be transformative; a loss would leave Anaptys as a pure royalty streamer. Monitor for any pre-PDUFA advisory committee meeting or settlement news.
Drug in focus
Jemperli
● Neutral Named in this press release- Impact
- Phase
- Approved (Phase 3 / registrational Phase 2 for additional indications)
- Time to market
- Already marketed (first FDA approval April 2021). Potential label expansion in dMMR/MSI-H rectal cancer would follow AZUR-1 data (H2 2026) and subsequent BLA filing.
- Next catalyst
- None dated
What to watchWatch for AZUR-1 Phase 2 registrational data in H2 2026, a positive readout (extending the 100% cCR rate seen in the MSK-collaboration study) could lead to an FDA filing for rectal cancer and support the ~$2.5B+ peak sales consensus. Be aware of the AnaptysBio royalty dispute going to trial in July 2026, which could alter Jemperli's economics. For a diversified phyla stock like GSK, Jemperli is a growth driver in oncology but not a stand-alone thesis.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 13 $46.25entry
- T+1 · 20h ago −1.12%α +0.79% · $45.73
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
AnaptysBio reported Q1 FY2027 (Sep 2026) collaboration revenue of $30.3M, below the $33.5M consensus, and GAAP EPS of $0.13, well below the $0.53 consensus estimate. The revenue decline was driven by the absence of a $50M milestone recognized in the year-ago quarter, partially offset by higher Jemperli royalties. The company highlighted the upcoming PDUFA date for Quimilza (Dec 12, 2026) and the pending litigation judgment against GSK/Tesaro (Q4 2026 or Q1 2027) as key catalysts.
Key Financial Metrics
Key Facts
- Collaboration revenue of $30.3M for Q1 FY2027 (Sep 2026), down from $76.3M in the year-ago quarter, missing the $33.5M consensus.
- GAAP net income from continuing operations of $3.9M ($0.13 per diluted share), down from $56.3M ($1.94 per diluted share) in Q1 FY2026, missing the $0.53 consensus EPS estimate.
- Cash and investments totaled $153.0M at Sep 30, 2026, down from $164.1M at Jun 30, 2026.
- Jemperli global net sales reached $1.0B for the nine months ended Sep 30, 2026, up 29% YoY; Anaptys receives 12% royalties on net sales between $1.0B and $1.5B annually.
- FDA target action date (PDUFA) of December 12, 2026, for Quimilza in generalized pustular psoriasis (GPP).
- Post-trial hearing in GSK/Tesaro litigation held Oct 20, 2026; judgment anticipated in Q4 2026 or Q1 2027.
Financial Impact
Revenue miss of ~$3.2M (10% below consensus) and EPS miss of $0.40 (75% below consensus) for the quarter. Cash burn of $11.1M in the quarter.
Risk Factors
- Revenue and EPS materially below consensus for the quarter.
- GSK litigation outcome is binary and uncertain; a loss would severely limit upside.
- Quimilza PDUFA in December 2026 is a binary regulatory event with no guarantee of approval.
- Cash burn continues; $153M cash provides limited runway if no milestone or royalty payments materialize.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3402246 |
Track record
28 reports on ANAB
9 of 18 bullish or bearish reports moved the stock their way by T+1. Best: +41.26% at T+60 after the Mar 3, 2026 report. 12 of 18 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $46.25 Now $45.73 −1.12% settles Nov 17
- Nov 12, 20264d ago Press Release Bearish 4/10 Viewing Entry $46.25 to $45.73 Now $45.73 +1.12% ▲ +1.12% −0.79% vs SPY
- Nov 6, 202610d ago Institutional Cluster Neutral 2/10 Entry $46.45 to $47.97 Now $45.73 −1.55% ▲ +3.27% +0.91% vs SPY
- Sep 21, 20268w ago Press Release Neutral 5/10 Entry $53.92 to $50.77 Now $45.73 −15.19% ▼ −5.84% −5.12% vs SPY
- Aug 12, 202613w ago Institutional Cluster Bullish 5/10 Entry $56.02 to $58.47 Now $45.73 −18.37% ▲ +4.37% +4.57% vs SPY
- Jun 29, 202620w ago 144 Bearish 6/10 Entry $67.50 to $65.43 Now $45.73 +32.25% ▲ +3.07% +2.93% vs SPY
- Jun 29, 202620w ago DEFA14A Neutral 2/10 Entry $67.50 to $65.43 Now $45.73 −32.25% ▼ −3.07% −2.93% vs SPY
- Jun 26, 202620w ago 144 Bearish 6/10 Entry $65.97 to $67.50 Now $45.73 +30.68% ▼ −2.32% −1.54% vs SPY
- Jun 22, 202621w ago 8-K Neutral 2/10 Entry $59.43 to $58.48 Now $45.73 −23.05% ▼ −1.60% −1.55% vs SPY
- Jun 17, 202621w ago 144 Bearish 5/10 Entry $57.51 to $59.99 Now $45.73 +20.48% ▼ −4.31% −4.63% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers